mTOR Inhibition by Everolimus Does Not Impair Closure of Punch Biopsy Wounds in Renal Transplant Patients

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are approved to prevent allograft rejection and control malignancy. Unfortunately, they are associated with adverse effects, such as wound healing complications that detract from more extensive use. There is a lack of prospective wound heal...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Transplant Direct
Main Authors: Dutt, Shelley B., Gonzales, Josephine, Boyett, Megan, Costanzo, Anne, Han, Peggy P., Steinberg, Steven, McKay, Dianne B., Jameson, Julie M.
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2017
Assuntos:
Kidney Transplantation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5381740/
https://ncbi.nlm.nih.gov/pubmed/28405603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TXD.0000000000000663
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares